Upsides

Adults with moderate to severe ulcerative colitis or Crohn's disease may benefit from this medication.

Entyvio has no known systemic (whole-body) immunosuppressive effects, but it is likely to increase a person's susceptibility to infections.

Unlike some other biologics, it specifically targets the gut rather than the entire body.

Entyvio's maintenance dose is typically 300mg given as an infusion every two months (8 weeks).

When older people over the age of 65 were given Entyvio, there were no differences in side effects or response.